- Home
- EE vs CERS Comparison
EE vs CERS Comparison
Compare EE & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EE
- CERS
- Stock Information
- Founded
- EE 2003
- CERS 1991
- Country
- EE United States
- CERS United States
- Employees
- EE N/A
- CERS N/A
- Industry
- EE Oil/Gas Transmission
- CERS EDP Services
- Sector
- EE Utilities
- CERS Technology
- Exchange
- EE Nasdaq
- CERS Nasdaq
- Market Cap
- EE 578.7M
- CERS 324.3M
- IPO Year
- EE 2022
- CERS 1997
- Fundamental
- Price
- EE $22.99
- CERS $1.63
- Analyst Decision
- EE Buy
- CERS Buy
- Analyst Count
- EE 6
- CERS 3
- Target Price
- EE $23.17
- CERS $3.17
- AVG Volume (30 Days)
- EE 229.3K
- CERS 1.6M
- Earning Date
- EE 11-06-2024
- CERS 10-31-2024
- Dividend Yield
- EE 0.43%
- CERS N/A
- EPS Growth
- EE 4.17
- CERS N/A
- EPS
- EE 1.12
- CERS N/A
- Revenue
- EE $898,981,000.00
- CERS $169,984,000.00
- Revenue This Year
- EE N/A
- CERS $15.25
- Revenue Next Year
- EE $27.38
- CERS $10.89
- P/E Ratio
- EE $20.64
- CERS N/A
- Revenue Growth
- EE N/A
- CERS 10.79
- 52 Week Low
- EE $13.38
- CERS $1.21
- 52 Week High
- EE $23.99
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- EE 59.69
- CERS 37.45
- Support Level
- EE $23.18
- CERS $1.71
- Resistance Level
- EE $23.96
- CERS $1.94
- Average True Range (ATR)
- EE 0.62
- CERS 0.11
- MACD
- EE -0.03
- CERS 0.01
- Stochastic Oscillator
- EE 52.50
- CERS 43.59
About EE Excelerate Energy Inc.
Excelerate Energy Inc is engaged in flexible LNG solutions, providing integrated services along the LNG value chain. The company offers a full range of flexible regasification services from FSRUs to infrastructure development, to LNG and natural gas supply.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.